Can You Trust Your Appointed Trustee?»
Q: What’s happened for securityholders?
A: A recent federal court decision, UMB Bank v. Brystol Meyers Squibb (“BMS”), serves as a cautionary tale for securityholders who replace their trustee without going through DTC.
Q: Why did the holders seek to remove and replace the trustee?
A: The holders of BMS’ Contingent Value Rights (“CVRs”) were entitled to over $6 billion in payments if the FDA approved marketing applications for three of BMS’ products by specified milestone dates. The CVR Agreement required BMS to use “diligent efforts” achieve the milestone dates. BMS failed to meet the milestone dates. Only the Trustee could bring suit against BMS and certain holders thought that a trustee appointed by them would be better suited to take actions against BMS under the CVR agreement.
Q: So, how was the trustee replaced?
A: Under the CVR Agreement, the Trustee could be removed by at least a majority of the “Holders” of the CVRs, meaning the registered holders (i.e., The Depository Trust Company (“DTC”), through Cede & Co.). However, an instrument of removal executed by a majority of the beneficial owners, but not DTC, was delivered to then-acting Trustee, Equiniti, purporting to replace it with a new Trustee, UMB Bank. Equiniti issued a notice, executed by BMS, confirming that UMB Bank was the new Trustee.
Q: How did things play out in court?
A: The CVR beneficial holders instructed UMB Bank to sue BMS for breach of the CVR contract for failing to use “diligent efforts” to meet the milestone dates, which it did. Two years after the case was filed—and after BMS’s initial motion to dismiss was denied—BMS filed a motion to dismiss for lack of standing because Equiniti was never properly removed as Trustee. UMB argued that Equiniti had authority to determine whether its removal was properly effectuated. The court granted the motion to dismiss: because DTC’s nominee, Cede & Co. was the true “Holder” of the CVRs and had not appointed UMB Bank as the new trustee, UMB Bank did not have standing to sue BMS. So, the “new” trustee was not the trustee at all.
Q: What does this mean for securityholders?
A: Holders seeking to remove and replace a Trustee or seeking to direct Trustees for amendments or other actions under indentures or other instruments with Trustees should be aware that instructions given by beneficial holders are subject to challenge and invalidation. Holders should instead seek the consent or proxy of DTC acting through Cede & Co.—this “Demand and Dissent” process can take time and holders are cautioned to ensure timetables take this into account. Failing to do so can be incurable.
Was 2024 the year when US-style priming finally took off in Europe?»
Q: Did US-style priming truly arrive in Europe in 2024?
A: Possibly, but it’s complex. The headlines from 2024 – like Hunkemoller, Altice France and Ardagh – suggest that Europe is seeing more creative priming maneuvers similar to those seen in the US. However, it’s still up for debate whether this is a true trend or just a few notable exceptions.
Q: What’s different about Europe compared to the US when it comes to creative priming transactions?
A: Size of capital stacks – and risk/reward – matters. In Europe, large cap debtors generally carry less debt than their US counterparts, potentially reducing the perceived upside reward for investors that participate in more creative (or riskier) priming transactions. Supporting this thesis are the exceptions of Ardagh and Altice France, both of which have seen more creative transactions within their sizeable capital stacks of c.$12 billion and €24 billion respectively.
Outside of these exceptions, the question remains whether there is enough upside reward in smaller capital structures to incentivize the pursuit of more creative transactions. Interestingly, we have seen bold moves in sub-$1bn cases like Hunkemoller (uptier), Oriflame (designating certain subs as unrestricted), and (looking further back) Intralot (dropdown), suggesting that investor appetite may be growing.
Q: What other factors may limit creative priming activity in Europe?
A: Relationships have a role to play. Markets are a people business. In Europe, the investor pool is smaller when compared to the US. Maintaining relationships may discourage overly aggressive maneuvers against other institutions and individuals that you see across any number of investments.
By contrast, family- or closely-owned companies (like Altice France, Ardagh and Intralot) may be more willing to consider creative priming transactions if they feel less restricted by the weight of cross-investment relationships.
Q: Are there legal or structural hurdles to priming in Europe?
A: Directors' duties across Europe are a patchwork of different regimes. Often, those regimes place stricter fiduciary responsibilities upon directors than those seen in the US – making it harder to justify moves that could put certain creditors at a disadvantage. Particularly the closer the debtor gets to being at risk of insolvency.
European financing agreements may also carry higher consent requirements than their US counterparts, particularly in the loan and intercreditor space.
The risk and cost downside of litigation is also significant. Hunkemoller, a Dutch debtor, now finds itself in the New York state courts defending a challenge to its uptier transaction.
Q: What is the outlook for liability management in Europe?
A: The jury’s still out. While some commentators suggest that US-style priming could take root in Europe, whether these transactions are capable of implementation is situation specific and will depend on the legal and relational dynamics at play. Each situation is nuanced, turning on the jurisdictions involved, documentary constraints, the nature and wider context of the liquidity need, and the attitudes of the particular debtor, its shareholder(s) and its investors.
Focus in on “what can we do” vs. “what can be done to us.” European creditors and debtors are now more attuned to their rights and vulnerabilities. This knowledge might be best used as a stick to influence behaviors and encourage inclusive soft amendments and extensions (A&Es) or pro-rata transactions.
As a final word: remember that liability management means different things to different people. The term can include the more vanilla and opportunistic transactions (such as debt buybacks at a discount). It does not always mean priming transactions where one investor group benefits at the direct expense of another.
Are European co-op agreements truly co-operative?»
Q: What’s driving the rise of co-operative agreements?
A: A trend from the US, co-ops are perceived to be a shield against priming – by forming a club of existing investors that agree to a set of rules or parameters in respect of a debtor and a potential transaction. That perception can hold true, provided the co-op group holds a sufficient majority of the debt to be able to block transactions that require lender consent.
Q: What are the limitations of co-operative agreements?
A: Co-ops may not be a perfect defense. They are most effective against actions that explicitly require investor consent under the finance documents. However, they can be less effective (or worse, ineffective) in scenarios where debtors have sufficient flexibility under their finance documents to execute a transaction without lender consent or if the co-op group does not hold a blocking stake where majority consent is required. Co-ops also frequently restrict debt trading while the co-op is on-foot, limiting market liquidity.
We have also seen the beginnings of debtor pushback against co-ops. Debtors may "weaponise" NDAs to create information imbalances and restrict communication between their investors, undermining the effectiveness of co-operative agreements. There is also growing market chatter questioning whether co-op agreements might be anticompetitive in some contexts, and whether debtors in new issuances can include terms to prohibit investors from talking to each other during the term of the debt.
Q: How should investors approach co-operative agreements?
A: Number one: don’t let fear of missing out dictate your decision. When presented with a co-op, investors should critically assess whether the co-op is appropriate for the specific situation. Signing-on just because others are (rumoured to be) doing so could lead to unintended consequences. Test the thesis behind the co-op. Speak to fellow investors and your trusted advisers.
Number two: be wary of two-tier co-ops. The recent trend sees creditors split into different groups within the co-op agreement, baking-in different economic returns between “day one” co-op signatories and subsequent co-op signatories. Instead of protecting creditors, these agreements could create tension and conflict within the co-op group – morphing the co-op from a shield into its own form of priming transaction.
Summary Conclusion Here. Summary Conclusion Here. Summary Conclusion Here. Summary Conclusion Here. Summary Conclusion Here. Summary Conclusion Here. Summary Conclusion Here. Summary Conclusion Here. Summary Conclusion Here. Summary Conclusion Here.